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BACKGROUND & AIMS: Patients with detectable hepatitis C virus
(HCV) RNA at the time of liver transplantation universally experi-
ence recurrent HCV infection. Antiviral treatment before trans-
plantation can prevent HCV recurrence, but existing interferon-
based regimens are poorly tolerated and are either ineffective or
contraindicated in most patients. We performed a trial to deter-
mine whether sofosbuvir and ribavirin treatment before liver
transplantation could prevent HCV recurrence afterward.
METHODS: In a phase 2, open-label study, 61 patients with HCV of
any genotype and cirrhosis (Child–Turcotte–Pugh score, 7) who
were on waitlists for liver transplantation for hepatocellular car-
cinoma, received up to 48 weeks of sofosbuvir (400 mg) and
ribavirin before liver transplantation. The primary end point was
the proportion of patients with HCV-RNA levels less than 25 IU/mL
at 12 weeks after transplantation among patients with this HCV-
RNA level at their last measurement before transplantation. RE-
SULTS: Sixty-one patients received sofosbuvir and ribavirin, and
46 received transplanted livers. The per-protocol efﬁcacy popula-
tion consisted of 43 patients who had HCV-RNA level less than 25
IU/mL at the time of transplantation. Of these 43 patients, 30
(70%) had a post-transplantation virologic response at 12 weeks,
10 (23%) had recurrent infection, and 3 (7%) died (2 from non-
function of the primary graft and 1 from complications of hepatic
artery thrombosis). Of all 61 patients given sofosbuvir and riba-
virin, 49% had a post-transplantation virologic response. Recur-
rence was related inversely to the number of consecutive days of
undetectable HCV RNA before transplantation. The most frequently
reported adverse events were fatigue (in 38% of patients), head-
ache (23%), and anemia (21%). CONCLUSIONS: Administration ofsofosbuvir and ribavirin before liver transplantation can prevent
post-transplant HCV recurrence. ClinicalTrials.gov: NCT01559844.
Keywords: Hepatitis C Virus; Liver Transplantation; HCV
Recurrence; Direct-Acting Antiviral Agents.
iver disease resulting from chronic hepatitis C virusL(HCV) infection is the leading indication for liver
transplantation in the United States, Europe, and Japan.1,2
Between 1995 and 2010 there were 126,862 new regis-
trants for primary liver transplantation in the United States,
of which more than 52,000 (41%) had HCV-associated liver
disease, primarily cirrhosis and hepatocellular carcinoma
(HCC).3 For patients with detectable HCV-RNA levels at the
time of transplantation, postoperative recurrence of HCV
infection was “immediate and universal.”4 Recurrent HCV
infection follows an aggressive course: 10%–30% of pa-
tients with recurrent HCV after transplantation develop
cirrhosis within 5 years, and more than 40% develop
cirrhosis within 10 years.5,6 Rates of graft loss and patient
mortality also are markedly higher for patients with recur-
rent HCV than for uninfected patients,5 and retrans-
plantation frequently is associated with a poor outcome.7
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ment to prevent recurrence of HCV infection after liver
transplantation. Antiviral therapy either before or immedi-
ately after liver transplantation has been studied, but results
from clinical studies have been mixed.8 Trials of pre-
transplantation antiviral therapy with interferon and riba-
virin have prevented HCV recurrence in only 20%–28% of
patients.9–13 Moreover, interferon-based treatment is poorly
tolerated, and is associated with life-threatening infections
and decompensation. Up to a third of patients discontinue
interferon-based treatment because of adverse events.13–15
Sofosbuvir is a nucleotide polymerase inhibitor of NS5B-
directed HCV-RNA replication. In clinical trials, administra-
tion of sofosbuvir with ribavirin was associated with rapid
decreases of HCV RNA to undetectable levels in patients
with HCV genotype 1, 2, 3, 4, and 6 infections.16,17 In more
than 3000 patients treated to date, sofosbuvir has been
shown to be safe, viral breakthrough during treatment has
been rare (and associated with nonadherence), and few
drug interactions have been observed.18,19 In addition, pa-
tients with hepatic impairment do not require modiﬁcation
of sofosbuvir dosage.20
We conducted this open-label study to determine if the
administration of up to 48 weeks of sofosbuvir and ribavirin
to HCV-infected patients with liver cancer before liver
transplantation could prevent post-transplant recurrence of
HCV infection.Materials and Methods
Patients
Patients were enrolled at 13 centers in the United States, 1
in New Zealand, and 1 in Spain. Eligible patients were at least
18 years old with a body mass index of 18 kg/m2 and
documented HCV infection of any genotype with an HCV-RNA
value greater than 104 IU/mL. Patients who had failed previ-
ous treatment for HCV were eligible. Patients were required to
be on the waiting list for liver transplantation (with anticipated
time until transplantation of <1 y) from a deceased donor.
Patients had HCC meeting the Milan criteria,21 with a biological
model for end-stage liver disease (MELD) score of less than 22,
and a Child–Turcotte–Pugh score of 7 or less, and had to be
eligible for a MELD exception score as per the policy of the
United Network for Organ Sharing. We chose to study patients
with HCC because they could be expected to undergo liver
transplantation within 1 year.Study Design
This phase 2, open-label, pilot study had 2 phases: a pre-
transplant treatment phase and a post-transplant follow-up
phase. During the pretransplant treatment phase, patients
received sofosbuvir (Gilead Sciences, Foster City, CA) adminis-
tered orally at a dose of 400 mg once daily, along with ribavirin
(Ribasphere; Kadmon, Warrendale, PA) administered orally as
a divided dose according to body weight (1000 mg/day in
patients with a body weight of <75 kg, and 1200 mg/day in
patients with a body weight of 75 kg). According to the
original study protocol, treatment lasted up to 24 weeks or
until time of transplant, whichever occurred ﬁrst. Patients whocompleted treatment before transplantation also were assessed
for sustained virologic response. Patients who relapsed after
stopping the study drug during the pretransplant treatment
phase and who were not found to have the S282T NS5B mu-
tation (which is associated with resistance to sofosbuvir) were
allowed to restart treatment and continue for an additional 24
weeks or until transplant. In a subsequent amendment, the
study design was changed to allow all patients who had not
reached 24 weeks of treatment at the time of the amendment to
continue treatment uninterrupted to 48 weeks or transplant.
This change was made after observing virologic relapse in 3
patients before transplantation in patients who stopped treat-
ment after completing 24 weeks.
For patients still receiving treatment at the time of trans-
plantation, dosing was discontinued within 24 hours before
transplant. During the post-transplant follow-up phase, patients
were followed up for 48 weeks for evidence of recurrent HCV
infection. All participating sites planned to use a standard post-
transplantation immunosuppressive regimen of solumedrol/
prednisone, tacrolimus, and/or mycophenolate mofetil (up to 2
g/day) for the ﬁrst 12 weeks after transplantation. Antibody
induction was prohibited during the study.
Study Assessments
The primary efﬁcacy end point was post-transplantation
virologic response (pTVR), deﬁned as HCV-RNA level less than
the lower limit of quantiﬁcation (LLOQ, 25 IU/mL) at 12 weeks
post-transplant in patientswho hadHCV-RNA levels less than the
LLOQ at their last assessment before transplantation. According
to the original study analysis plan, only patients who received at
least 12 weeks of treatment before transplantation were to be
included in the efﬁcacy analysis. However, this restriction was
not used in the analysis, therefore the efﬁcacy population in-
cludes patients who received any duration of treatment (Table 2
shows the overall results for both populations). Other secondary
efﬁcacy end points included an evaluation of safety and tolera-
bility. Plasma HCV-RNA levels were measured with the COBAS
TaqMan HCV Test, version 2.0, for use with the High Pure System
(Roche Molecular Systems, Branchburg, NJ).
Resistance Testing
Population sequencing of the HCV NS5B-encoding region of
the viral polymerase was performed using standard sequencing
technology on all baseline (pretreatment) viral samples. Deep
sequencing with an assay cut-off value of 1% was performed
for all patients who qualiﬁed for resistance testing as a result of
an incomplete virologic response on treatment, post-treatment
relapse, post-transplant recurrence, or early termination with
HCV-RNA levels greater than 1000 IU/mL. Nucleoside inhibitor-
associated variants were deﬁned as N142T, L159F, L230F, and
V321A, and any substitutions at position S282 of NS5B. Drug
susceptibility testing was performed using a replicon system
with either patient population samples or site-directed
mutants.
Statistical Methods
Assuming an observed week 12 pTVR rate of 50%, we
calculated that a sample size of 31 would be sufﬁcient to show
that the 1-sided 95% upper bound of the conﬁdence interval
(using a normal approximation of the binomial) for the
Table 1.Baseline Characteristics
Characteristic All patients dosed (n ¼ 61)
All patients transplanted with HCV-RNA level
<25 IU/mL at time of transplant (N ¼ 43)
Median age, y (range) 59 (46–73) 59 (50–73)
Male sex, n (%) 49 (80) 32 (74)
Race, n (%)
White 55 (90) 40 (93)
Black 6 (10) 3 (7)
Ethnicity, n (%)
Hispanic or Latino 12 (20) 8 (19)
Non-Hispanic 49 (80) 35 (81)
Median body mass index, kg/m2 (range) 27.4 (20.0–58.7) 27.1 (20.0–58.7)
Prior HCV treatment—no. (%)
No 15 (25) 9 (21)
Yes 46 (75) 34 (79)
Prior null response 11/46 (24) 6/34 (18)
Prior partial response 11/46 (24) 9/34 (26)
Prior breakthrough 3/46 (7) 3/34 (9)
Prior relapse 9/46 (20) 7/34 (21)
Unknown prior response 12/46 (26) 9/34 (26)
Median baseline HCV-RNA level, log10 IU/mL (range) 6.2 (4.1–7.2) 6.3 (4.1–7.0)
Baseline viral load, n (%)
<6 log10 IU/mL 20 (33) 14 (33)
>6 log10 IU/mL 41 (67) 28 (67)
HCV genotype, n (%)
1a 24 (39) 15 (35)
1b 21 (34) 16 (37)
2 8 (13) 6 (14)
3a 7 (11) 5 (12)
4a 1 (2) 1 (2)
IL28B genotype, n (%)
CC 13/60 (22) 10 (23)
CT 39/60 (65) 28 (65)
TT 8/60 (13) 5 (12)
Baseline ALT level > 1.5 upper limit of normal, n (%) 26 (43) 17 (40)
Median glomerular ﬁltration rate, mL/min (range) 113 (63–211) 111 (63–209)
Baseline Child–Turcotte–Pugh score, n (%)
5 26 (43) 18 (42)
6 18 (30) 15 (35)
7 14 (23) 9 (21)
8a 3 (5) 1 (2)
Baseline MELD score, n (%)
6 5 (8) 4 (9)
7 18 (30) 14 (33)
8 12 (20) 6 (14)
9 9 (15) 7 (16)
10 6 (10) 4 (9)
11 8 (13) 7 (16)
13 2 (3) 1 (2)
14 1 (2) N/A
ALT, alanine aminotransferase.
aThese patients were deemed by the site to have a Child–Turcotte–Pugh score of 7 during screening, but after the initiation of
dosing the central laboratory found them to have a Child–Turcotte–Pugh score of 8.
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Appendix for a detailed description of the statistical methods.Study Oversight
The study was approved by the institutional review board
or independent ethics committees at participating sites and was
conducted in compliance with the Declaration of Helsinki, Good
Clinical Practice guidelines, and local regulatory requirements.The study was designed and conducted according to protocol
by the sponsor (Gilead) in collaboration with the principal in-
vestigators. The sponsor collected the data, monitored
study conduct, and performed the statistical analyses. All au-
thors had access to the data and assumed responsibility for
the integrity and completeness of the reported data. The
manuscript was prepared by Gilead Sciences with input from
all authors. All authors reviewed and approved the ﬁnal
manuscript.
Table 2.Post-Transplant Virologic Response by Visit for
Patients With HCV-RNA Level Less Than the LLOQ
at the Last Measurement Before Liver
Transplantation
Sofosbuvir-
ribavirin
for 12 weeks
(N ¼ 32)
Sofosbuvir-
ribavirin
for any duration
(N ¼ 43)
Post-transplant week 1
<LLOQ, n/N (%) 28 (88%) 37 (86%)
90% CI 74%96% 74%94%
Post-transplant week 2
<LLOQ, n/N (%) 26 (81%) 35 (81%)
90% CI 66%92% 69%90%
Post-transplant week 4
<LLOQ, n/N (%) 24 (75%) 31 (72%)
90% CI 59%87% 59%83%
Post-transplant week 8
<LLOQ, n/N (%) 24 (75%) 31 (72%)
90% CI 59%87% 59%83%
Post-transplant week 12
<LLOQ, n/N (%) 24 (75%) 30 (70%)
90% CI 59%87% 56%81%
NOTE. HCV RNA was analyzed using the Roche TaqMan
version 2.0 assay for use with the High Pure system with a
limit of quantiﬁcation of 25 IU/mL.
CI, conﬁdence interval.
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Study Patients and Disposition
Supplementary Figure 1 shows the disposition of pa-
tients throughout the study. Of the 92 patients screened, 63
were enrolled in the study, and 61 received at least 1 dose
of study drug (Supplementary Table 1). Of the 61 patients
who received at least 1 dose of study drugs, 46 underwent
a transplantation and 15 discontinued the study before
transplantation. Of the 46 patients who underwent
transplantation, 43 had HCV-RNA level less than the LLOQ
at the time of transplantation. These 43 patients had been
on the waiting list for liver transplantation for a mean of
295 days (median, 128 days). Baseline demographic
characteristics for the 61 patients who received study
drugs and the 43 patients who underwent transplantation
and had HCV-RNA level less than the LLOQ are shown in
Table 1. Of the 61 dosed, more than 70% were infected
with genotype 1 HCV, and the majority (79%) previously
received treatment for their HCV infection. This article
describes the efﬁcacy results in 43 patients who under-
went transplantation with an HCV-RNA level less than the
LLOQ and safety and resistance results from the entire
treated population.Efﬁcacy
Pretransplant treatment phase. In the 61 subjects
who received study drug. the median duration of exposure
to study drugs was 21 weeks (range, 2.3–52.3 wk). Treat-
ment with sofosbuvir and ribavirin resulted in rapidsuppression of circulating virus with a median decrease in
HCV-RNA level of 3.93 log10 IU/mL after 1 week of treat-
ment. By the fourth week of treatment, 54 of the 58 patients
(93%) receiving treatment had an HCV-RNA level less than
the LLOQ. The rate and amount of decrease in HCV-RNA
levels did not differ by prior HCV treatment history or
Child–Turcotte–Pugh class.
Post-transplant follow-up phase. Of the 46 patients
who underwent transplantation, 43 had HCV RNA less than
the LLOQ at the time of transplantation and represent the
prespeciﬁed group for which we determined treatment ef-
ﬁcacy. The median donor age for the 38 of 43 grafts for
whom donor information was available was 38 years (range,
19–75 y). Of the 43 patients with an HCV-RNA level less
than the LLOQ at the time of transplantation, 30 (70%)
achieved pTVR12 (Table 2). For all 30 patients with pTVR,
HCV-RNA level was undetectable (target not detected) at
post-transplant week 12. Of the 13 patients not achieving
pTVR12, 10 patients had conﬁrmed HCV recurrence
(Supplementary Table 2) and 3 patients died immediately
after transplant (details later). When expressed as a per-
centage of the total population who received study treat-
ment, 49% (30 of 61) achieved pTVR.
Rates of pTVR12 in various subgroups are shown in
Supplementary Table 3. In univariate logistic regression anal-
ysis, pTVRwas associated positivelywithHCV genotypes other
than HCV1b infection and a greater number of consecutive
dayswith undetectable HCV-RNA level before transplantation.
However, in multivariate logistic regression analysis, the
only statistically signiﬁcant predictor of pTVR was the
number of consecutive days a patient’s HCV-RNA level was
undetectable (target not detected) before transplantation
(Figure 1, Supplementary Table 4). This result was supported
by a separate analysis, which found that themedian number of
consecutive days with undetectable HCV-RNA level before
transplantation was 5.5 days (range, 0–88 days) for patients
with observed recurrence compared with 99.5 days (range,
1–473 days) for patients with pTVR (P < .001, 2-sided Wil-
coxon rank sum test). Outcomes did not appear to correlate
with donor age or other donor characteristics, although given
the small numbers of patients with recurrence and incomplete
donor information for all patients, this observation is
preliminary.
Resistance analyses. Baseline population sequencing
detected the presence of 2 variants associated with resis-
tance to nucleotide inhibitors: L159F in 4 patients and
N142T in 1 patient. Resistance analysis by deep sequencing
was performed for 29 of 61 patients who showed virologic
failure before transplantation or recurrence after trans-
plantation with HCV-RNA level greater than 1000 IU/mL. No
NS5B mutant S282T was detected in any patient samples
analyzed. Twelve of 29 patients developed other nucleoside
inhibitor resistance–associated variants and only as minor
subpopulations (<10% of population) in 11 of 12 patients
(Table 3). All 4 patients with L159F at baseline relapsed and
had the L159F variant at the time of relapse. The patient
with N142T at baseline achieved sustained virological
response 12. Phenotypic testing of the patient samples and
site-directed mutants of the variants (N142T, L159F, V321A,
Figure 1. No recurrence/
recurrence by days HCV
RNA continuously target not
detected before liver trans-
plantation. TND, Target not
detected.
Table 4.Adverse Events and Hematologic Abnormalities
Event Sofosbuvir-ribavirin (N ¼ 61)
Median duration of exposure to
study regimen, wk (range)
21.0 (2.3–52.3)
Any adverse event 54 (89)
Any serious adverse event 11 (18)
Any grade 3 adverse event 11 (18)
Hematologic event
Hemoglobin level, n (%)
Patients with at least 1
postbaseline hemoglobin
value <10 g/dL
18 (30)
Patients with at least 1
postbaseline hemoglobin
value <8.5 g/dL
3 (5)
Absolute lymphocyte count,
n (%)
350 to <500 per mm3 5 (8)
<350 per mm3 5 (8)
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sofosbuvir (sofosbuvir fold-change, <2.0; data not shown).
Observed minor variants, S282R and S282G, also were
introduced by site-directed mutagenesis in replicons but
failed to replicate in vitro precluding phenotypic analysis.
No ribavirin treatment-associated mutations, M390I or
F415Y, developed in patients who qualiﬁed for resistance
testing.
Overall Safety
Eighty-nine percent of the 61 patients receiving at least 1
dose of drug reported an adverse event (Table 4). The most
common events were fatigue (38% of patients), headache
(23% of patients), anemia (21% of patients), nausea (16% of
patients), and rash (15% of patients). Two subjects dis-
continued treatment because of adverse events (pneumo-
nitis and sepsis/acute renal failure). Eleven patients (18%)
experienced serious adverse events; 3 of those eventsPlatelets
25,000 to <50,000 per mm3 4 (7)
Absolute neutrophil count, n (%)
500 to <750 per mm3 2 (3)
Common adverse events, n (%)a
Fatigue 23 (38)
Headache 14 (23)
Anemia 13 (21)
Nausea 10 (16)
Rash 9 (15)
Cough 7 (11)
Dyspnea 7 (11)
Insomnia 7 (11)
Constipation 6 (10)
Pruritus 6 (10)
aEvents occurring in 10% of patients.
Table 3.Development of Nucleoside Inhibitor
Treatment–Associated Minor Variants in NS5B
NS5B nucleoside
inhibitor treatment–
associated variants
Number of
patients
Viral population
with developed
variant, %
N142T 2/61 1.0, 1.3
L159F 5/61 2.1, 3.2, 6.1, 9.5, 79.1
S282G 1/61 6.1
L320F 3/61 1.6, 2.9, 7.3
L159F, S282R, L320F, V321Aa 1/61 1.1–3.0
aOne patient with incomplete response to treatment had
detectable L159F, S282R, L320F, and V321A.
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lular carcinoma, obstructive umbilical hernia, and pyrexia
(Supplementary Table 5 shows the full list of treatment-
emergent serious adverse events). One treatment-emergent
death as a result of sepsis occurred 15 days after the last
dose of study drug. Four additional non–treatment-emergent
deaths occurred as a result of pneumonitis, liver graft failure,
cardiogenic shock, and sepsis. None were attributed by the
investigators to study treatment.
Laboratory ﬁndings at baseline were consistent with
decompensated cirrhosis (thrombocytopenia, increased to-
tal bilirubin, and prolonged prothrombin time). Twenty-one
patients (34%) experienced grade 3 laboratory abnormal-
ities and 7 patients (11%) experienced grade 4 laboratory
abnormalities. The most common grade 3 or 4 laboratory
abnormalities were a grade 3 decrease in hemoglobin level
(4.5 g decrease from baseline or absolute value of 7.0–8.9
g/dL) in 15% of patients and grade 3 hyperglycemia
(251–500 mg/dL) in 11% of patients. A mean increase of
0.26 mg/dL in total bilirubin level was seen at week 12 of
treatment; 5 patients had grade 3 hyperbilirubinemia
(2.6–5.0  upper limit of normal) and 1 patient had grade 4
hyperbilirubinemia (>5.0  upper limit of normal). During
treatment, alanine aminotransferase level decreased from a
baseline median of 76 IU/L to a median alanine amino-
transferase level of 30 IU/L or less by week 2, which was
sustained throughout treatment. Hemoglobin values also
decreased during treatment (consistent with the known
effects of ribavirin treatment), with a mean decrease from
baseline (baseline mean, 13.5 g/dL) to week 24 of 1.5 g/dL;
18 (30%) patients had at least 1 hemoglobin measurement
of less than 10 g/dL and 3 patients (5%) had a hemoglobin
measurement of less than 8.5 g/dL. Twelve (20%) patients
had ribavirin dose reductions during treatment. No patients
received blood products or epoetin during the study.
Platelet counts increased from a baseline mean of 107 
103/mL to 120  103/mL at week 24. MELD scores remained
stable before transplant. Three patients experienced pro-
gression of liver cancer that placed them outside the Milan
criteria, and as a result were removed from the waiting list
for liver transplantation. Two of these patients stopped
treatment at week 24 and relapsed, and the other patient,
who received 48 weeks of treatment, reached sustained
virological response 12.Discussion
In this pilot study, sofosbuvir and ribavirin before liver
transplantation prevented recurrence of HCV infection in
70% of patients with chronic HCV infection and liver cancer
who achieved an HCV-RNA level less than 25 IU/mL before
transplantation and in almost half of the total patients in the
study. This population of patients with compensated or
mildly decompensated cirrhosis included patients with
characteristics historically associated with lower rates of
response to antiviral therapy: high viral load, non-CC ge-
notype, and prior nonresponse to interferon therapy. The
rate of discontinuation owing to adverse events was low,
and most observed events were those associated commonlywith ribavirin therapy—fatigue, anemia, headache, and
nausea—as were the laboratory abnormalities of decreased
hemoglobin and increased bilirubin levels.
This study provides proof of concept that virologic sup-
pressionwithout interferon signiﬁcantly can reduce the rate of
recurrent HCV after liver transplantation. The presumed
absence of extrahepatic reservoirs of viral replication, the
potencyof the antiviral regimen, andhost immuneresponseall
are possible determinants of clinical outcome. Although the
reservoir of HCV replication largely is limited to the liver, HCV
RNA has been detected in peripheral blood, suggesting
possible sites of “occult infection.”22–25 In this study, we have
shown that removal of the infected liver in the setting of un-
detectable levels of HCV RNA in the blood is associated with
low rates of recurrence, suggesting that other possible reser-
voirs of infection may not be as important as previously
thought. The rapid decrease in HCV-RNA level with direct-
acting antiviral therapy, including sofosbuvir, has been
modeled using a multiscale age-structured approach,26,27
indicating a triphasic pattern of serum viral load decrease.
Themodel suggests that6–8weeksof suppressionofHCVRNA
(continuously undetectable) is required for complete virologic
clearance. The magnitude of HCV-RNA decrease in these pa-
tients also is similar to that observed with sofosbuvir in phase
3 studies, reﬂecting the enhanced rates of loss of intracellular
viral RNA, replication templates, and infected cells.
The results from this trial compare favorably with those
observed in other trials of pretransplantation antiviral
therapy.9–13 In prior small, mostly single-center, studies
using regimens containing peginterferon and ribavirin, rates
of post-transplant virologic response ranged from 20% to
28%.14,15 Treatment was associated with high rates of dis-
continuations for adverse events and high rates of serious,
often life-threatening, complications. In the only randomized
controlled trial of pretransplantation antiviral treatment
conducted to date, patients with MELD scores of 20 or less
received a low accelerating dose regimen of peginterferon
alfa-2b and ribavirin or no treatment.13 Of the 44 patients
who underwent treatment in that study, 26 (59%) achieved
an undetectable HCV-RNA level by the time of trans-
plantation. The rate of post-transplant response among
treated patients was 22% in patients with HCV genotype 1,
4, or 6 infection, and 29% in patients with genotype 2 or 3
infection. The response rate was associated with duration of
treatment—no patients who received fewer than 8 weeks of
treatment achieved a sustained response, compared with
18% among patients who received 8–16 weeks of treatment
and 50% among those who received more than 16 weeks of
treatment with peginterferon-ribavirin. Forty-six percent of
treated patients also had serious adverse events during
pretransplantation treatment.
Deep sequencing analysis of patients with pretransplant
virologic failure or recurrence post-transplant showed no
evidence of the S282T mutant in NS5B. These results are
consistent with the low prevalence of this NS5B mutant
after relapse after sofosbuvir treatment as previously
described.16,17,28–30 However, minor subpopulations of
other nucleoside inhibitor treatment–associated variants
were observed in multiple patients. The observed
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encode for marginal reductions in susceptibility to sofos-
buvir that cannot be measured with current in vitro sys-
tems. It is possible that there is ongoing low-level
replication during treatment in some patients, perhaps
owing to the presence of the HCC lesions, resulting in an
enrichment of these mutants relative to wild-type and then
transient detection at relapse/recurrence before wild-type
dominates again. The clinical signiﬁcance of the appear-
ance of these minor variants remains to be determined.
Because of the small size of this study, any conclusions
must be considered preliminary in nature and require
further evaluation in larger studies. Extrapolation of these
results to all patients with HCV awaiting liver transplant is
limited by the fact that the population studied comprised
patients with compensated or mildly decompensated liver
disease undergoing transplantation for hepatocellular car-
cinoma. At the time the study was designed, the safety of
sofosbuvir had not been evaluated in decompensated liver
disease, and we therefore chose patients with a diagnosis of
hepatocellular carcinoma meeting the Milan criteria so that
the efﬁcacy of the regimen for preventing post-transplant
recurrence could be evaluated in patients with lower
MELD scores, but who would be expected to undergo liver
transplantation within 1 year. Studies of sofosbuvir regi-
mens in patients with more advanced disease pretransplant
are underway. The lack of a control arm to deﬁne efﬁcacy
and tolerability of the regimen was another shortcoming,
although ascertainment bias is unlikely given the universal
recurrence of HCV in untreated patients.
The majority of patients in this study had an undetect-
able viral load at the time of transplant and achieved pTVR.
However, nonresponse and relapse were observed in a
substantial proportion of patients, which led to re-infection
of the allograft. It is unknown whether continuation of
sofosbuvir and ribavirin through the post-transplant period
in patients with a shorter duration of virologic suppression
before transplantation could reduce rates of recurrence.
Alternatively, higher rates of pTVR may be possible through
the addition of another direct-acting antiviral to pretrans-
plant sofosbuvir and ribavirin.
In conclusion, therapy with sofosbuvir and ribavirin
before liver transplantation prevented the recurrence of
HCV infection after transplantation in 70% of patients who
had undetectable levels of HCV RNA before transplantation.
Given the burden of disease owing to HCV recurrence post-
transplantation—the increased morbidity, mortality, and
costs—these results provide hope for patients in need.
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